Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Patent
1992-08-10
1994-10-04
Kim, Kay K.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
514 8, 514 12, 514 21, 5303917, 530394, 424832, A61K 3944, A61K 3704, C07K 1702
Patent
active
053524470
ABSTRACT:
A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.
REFERENCES:
patent: 4520226 (1985-05-01), Neville, Jr. et al.
patent: 4830962 (1989-05-01), Gelfand et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4956453 (1990-09-01), Bjorn et al.
patent: 4981979 (1991-01-01), Sivam
patent: 5066490 (1991-11-01), Neville, Jr. et al.
patent: 5154924 (1992-10-01), Friden
patent: 5167956 (1992-12-01), Neville, Jr. et al.
patent: 5182107 (1993-01-01), Friden
patent: 5208021 (1993-05-01), Johnson et al.
Colombatti et al, The Journal of Biological Chemistry, vol. 261, No. 7, pp. 3030-3035, Mar. 5, 1986.
Akiyama et al, Cancer Research, vol. 45, pp. 1005-1007, 1985.
Seto et al., Cancer Research, vol. 42, pp. 5209-5215, 1982.
Hwang et al, Cancer Research, vol. 44, pp. 4578-4586, Oct., 1984
Weizaecker et al (1981) J. Neurology 224:183-192.
Neville Jr. et al (1989) J. Biol. Chem. 264(25) 14653-61.
Youle et al (1986) J. Immunology 136(1):93-98.
Walker et al (1978) J. Neurosurg. 49: 333-343.
Zovickian et al (1988) J. Neurosurg. 68: 767-774.
Osband et al (1990) Immunology Today 11(6): 193-195.
Waldmann (1991) Science 252: 1657-252.
Zovickian et al (1987) J. Neurosurg. 66:850-861.
Jeffries et al (1984) Nature 312: 162-163.
U. S. Army Medical Res. Institute of Infectious Diseases pp. 95-96 (1981).
Greenfield et al. Science Magazine (1987) 238, pp. 536-539.
Laird et al, J. of Virology, (1976), 19, pp. 220-227.
Johnson Virginia
Youle Richard J.
Kim Kay K.
The United States of America as represented by the Secretary of
LandOfFree
Immunotoxins for treatment of intracranial lesions and as adjunc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotoxins for treatment of intracranial lesions and as adjunc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotoxins for treatment of intracranial lesions and as adjunc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-579924